number of access : ?
number of downloads : ?
ID 110046
Title Alternative
局所進行膵癌に対するゲムシタビン定速静注及びS-1併用化学放射線療法の第Ⅰ/Ⅱ相試験
FDR-gem plus S-1 with RT for pancreatic cancer
Author
Goji, Takahiro University of Tokushima KAKEN Search Researchers
Kimura, Tetsuo University of Tokushima KAKEN Search Researchers
Takehara, Masanori University of Tokushima
Kagemoto, Kaizo University of Tokushima
Okada, Yasuyuki University of Tokushima
Okazaki, Jun University of Tokushima
Takaoka, Yoshifumi University of Tokushima
Miyamoto, Yoshihiko University of Tokushima
Matsumoto, Sayo University of Tokushima
Sueuchi, Tatsuhisa University of Tokushima
Takaoka, Toshi University of Tokushima
Kimura, Masako University of Tokushima
Sato, Yasuhiro Hokkaido Cancer Center
Sagawa, Tamotsu Hokkaido Cancer Center
Fujikawa, Koji Hokkaido Cancer Center
Keywords
Pancreatic cancer
Chemoradiotherapy
Fixed-dose-rate gemcitabine
S-1
gemcitabine
radiosensitizer
Content Type
Thesis or Dissertation
Description
Purpose: This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data.
Methods: Patients with unresectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400mg/m2, 5mg/m2/min) on days 1, 8, 22, 29 and 60mg/m2 of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28fractions) was delivered concurrently.
Results: Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300mg/m2 of gemcitabine and 60mg/m2 of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rate were 16.0 months and 73%, respectively.
Conclusion: The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC.
Journal Title
Cancer Chemotherapy and Pharmacology
ISSN
03445704
14320843
NCID
AA00598397
AA1161885X
Publisher
Springer nature
Volume
76
Issue
3
Start Page
615
End Page
620
Published Date
2015-07-29
Remark
内容要旨・審査要旨・論文本文の公開:
内容要旨・審査要旨:LID201704141008.pdf
論文本文:k3028_fulltext.pdf
本論文は, 著者Takahiro Gojiの学位論文として提出され, 学位審査・授与の対象となっている。
The final publication is available at link.springer.com.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
ETD
MEXT report number
甲第3028号
Diploma Number
甲医第1332号
Granted Date
2017-03-23
Degree Name
Doctor of Medical Science
Grantor
Tokushima University
departments
University Hospital
Medical Sciences